William Blair analyst Brandon Vazquez has maintained their bullish stance on PEN stock, giving a Buy rating on July 23.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Brandon Vazquez has given his Buy rating due to a combination of factors that highlight Penumbra’s promising outlook. The company’s sales and earnings per share exceeded expectations by 4%, driven by strong performance across its portfolio, particularly in overseas embolization. This success prompted an increase in guidance, although there are concerns about a potential slowdown in the second half of the year, which Vazquez attributes to management’s conservative approach.
Furthermore, the momentum in the venous thromboembolism segment and the introduction of new products and markets in embolization are expected to support continued growth. The upcoming results from the STORM-PE study and the anticipated approval of Thunderbolt for stroke treatment could provide additional growth opportunities in 2026. Additionally, the establishment of new sales teams for embolization and vascular products is likely to enhance market penetration. Despite the stock being down nearly 30% from its summer highs, Vazquez believes the prospects for the second half and 2026 are compelling, presenting a strategic opportunity for investors.
Vazquez covers the Healthcare sector, focusing on stocks such as Neogen, Elanco Animal Health, and PROCEPT BioRobotics. According to TipRanks, Vazquez has an average return of 1.8% and a 55.56% success rate on recommended stocks.
In another report released on July 23, Jefferies also reiterated a Buy rating on the stock with a $325.00 price target.